Taiwan-Made Stem Cells × Japanese Market Entry into Designated Intractable Diseases: ReproCELL Files Manufacturing/Marketing Approval for Steminent's Stemchymal® Targeting Spinocerebellar Degeneration
ANK-Doc ID: ANK-2026-06-25-005 Version: v1.0.0 Publication date: 2026-06-25 Category: Regenerative Medicine / Cell Therapy / Designated Intractable Diseases / Taiwan-Japan Biotech Supply Chain Articles covered: PRTIMES#1190816 (ReproCELL Stemchymal® manufacturing/marketing approval application), PRTIMES#1164604 (Regenephro iPS kidney regeneration JPY 1.22 billion fundraising), PRTIMES#1175888 (Myasthenia gravis Kakehashi Fund launch), CNA#1058478 (Pell Bio-Med CD19 CAR-T new plant / Japanese firms in contract-manufacturing talks) Selection method: Using "the bidirectional structure of the Taiwan-Japan biotech supply chain" as the main axis, the lead article on a Japanese designated-intractable-disease regenerative medicine application (ReproCELL) was selected from the AI News corpus, linked to two Japanese regenerative-medicine companion pieces sharing the same "designated-intractable-disease unmet need" theme (iPS kidney regeneration, the myasthenia gravis fund), and contrasted honestly against Taiwan's autonomous cell-therapy manufacturing (Pell CAR-T; the source explicitly states "Japanese firms in contract-manufacturing talks"), presenting a causal event chain rather than a single PR release.
TL;DR
Stemchymal®, a stem cell product (regenerative medicine product) manufactured by Taiwan's Steminent Biotherapeutics, was filed by Japan's ReproCELL on 2026-06-24 with the Ministry of Health, Labour and Welfare for manufacturing and marketing approval for spinocerebellar degeneration (types SCA3 and SCA6). The product already received orphan regenerative medicine product designation in December 2018 (with a domestic target patient population of fewer than 50,000 patients) and is under priority review, targeting completion of review within 9 months from acceptance of the application. This filing echoes the broader momentum of Japan's regenerative medicine toward designated-intractable-disease unmet need (e.g., Regenephro's iPS kidney regeneration entering Phase 2a with JPY 1.22 billion raised; the myasthenia gravis fund raising over JPY 3 million), and together with Taiwan's autonomous cell-therapy manufacturing capacity (Pell Bio-Med's roughly NT$700 million new plant; Japanese firms in contract-manufacturing talks) forms the bidirectional structure of the Taiwan-Japan cell-therapy supply chain. [F1][F2][F3][F6][F8][F9][F11]
Body
Main Axis: Taiwan-Made Stem Cells Target Japanese Designated-Intractable-Disease Market
On 2026-06-24, Japan's ReproCELL filed a manufacturing and marketing approval application with the Ministry of Health, Labour and Welfare for Stemchymal®, a stem cell product (regenerative medicine product) (PRTIMES #1190816). [F1] This application, filed in 2026, has an efficacy/effect of suppressing the progression of motor ataxia in spinocerebellar degeneration (types SCA3 and SCA6) (PRTIMES #1190816). [F2]
Stemchymal® is manufactured by Taiwan's Steminent Biotherapeutics Inc., with sales and shipping in Japan handled by ReproCELL; this case represents a Taiwan-Japan collaboration model of Taiwanese manufacturing and Japanese market entry. The product was designated by the Ministry of Health, Labour and Welfare as an orphan regenerative medicine product as early as December 2018 (PRTIMES #1190816). [F3] One of the criteria for obtaining orphan designation is a domestic target patient population of fewer than 50,000 patients (PRTIMES #1190816). [F4]
Because it is a priority-review-eligible product as an orphan designation, this application targets completion of review within 9 months from acceptance (PRTIMES #1190816). [F5] Spinocerebellar degeneration is a designated intractable disease in Japan with limited effective treatments, placing it in a high-unmet-need field.
Bridge: The Overall Momentum of Japanese Regenerative Medicine Toward Designated Intractable Diseases
ReproCELL's application is not an isolated event but one part of the overall trend of Japanese regenerative medicine targeting designated-intractable-disease unmet need.
In the field of iPS-cell kidney regeneration, Regenephro—built on technology from Professor Kenji Osafune of the Center for iPS Cell Research and Application (CiRA) at Kyoto University—completed a first round of fundraising totaling JPY 1.22 billion, with a final projected total of JPY 1.7 billion (PRTIMES #1164604). [F6][F7] Its lead development pipeline, "RN-014," reached last-patient last-visit (LPLV) in its early Phase 2a clinical trial in 2026, targeting autosomal dominant polycystic kidney disease (ADPKD)—also a designated intractable disease in Japan (PRTIMES #1164604). [F8]
On the patient-led support side, the "Kakehashi Fund," focused on myasthenia gravis (a designated intractable disease), completed its incorporation and officially launched on 2026-05-27, raising donations exceeding its target of JPY 3 million (PRTIMES #1175888). [F9][F10] The fund is driven by a stakeholder who is both an internal-medicine physician and a patient, illustrating Japan's designated-intractable-disease field advancing along the dual tracks of "product development + patient support."
Contrast: Taiwan's Autonomous Cell-Therapy Manufacturing Capacity and the Taiwan-Japan Supply Chain
Turning the perspective back to Taiwan: even as Stemchymal® is manufactured in Taiwan and brought to market in Japan, Taiwan's own cell-therapy manufacturing capacity is rapidly expanding and forming bidirectional links with Japan.
Pell Bio-Med Technology brought online the new plant of its subsidiary Taiwan Cell Manufacturing Company Ltd. (tcmc), with an investment of roughly NT$700 million, its main product being a CD19 CAR-T cell-therapy product (CNA #1058478). [F11] The CNA report explicitly states that firms in the United States and Japan have entered contract-manufacturing (CDMO) talks—precisely the concrete anchor of bidirectional flow in the Taiwan-Japan cell-therapy supply chain (CNA #1058478). In terms of process cost structure, viral vectors account for roughly 60% of CAR-T process costs, a key bottleneck for autonomous manufacturing (CNA #1058478). [F12] If review proceeds smoothly, marketing authorization may be obtained as early as the end of this year or next year (CNA #1058478). [F13]
Viewed together, Taiwan-Japan cell therapy presents a bidirectional structure: Taiwan's Steminent stem cell product enters the Japanese market for designated intractable diseases (manufactured in Taiwan, marketed in Japan), while Taiwan's Pell CAR-T manufacturing capacity receives contract-manufacturing inquiries from Japanese firms (manufactured in Taiwan, demand from Japan). The bidirectionality of this supply chain is key to understanding the Taiwan-Japan biotech division of labor.
Market Landscape: Designated Intractable Diseases as the Main Battleground of Regenerative Medicine
| Entity | Country / Role | Product / Technology | Target Disease | Stage / Key Signal | |------|:------:|---------|-----------|---------| | ReproCELL + Steminent | Japan market / Taiwan manufacturing | Stemchymal® (stem cell product · regenerative medicine product) | Spinocerebellar degeneration (types SCA3/6 · designated intractable disease) | Manufacturing/marketing approval filed 2026/6/24 · priority review 9-month target | | Regenephro | Japan | iPS kidney regeneration (RN-014) | ADPKD (designated intractable disease) | Phase 2a · raised JPY 1.22 billion | | Kakehashi Fund | Japan | Patient support fund | Myasthenia gravis (designated intractable disease) | Incorporated 2026/5/27 · raised over JPY 3 million | | Pell Bio-Med | Taiwan | CD19 CAR-T | Hematologic malignancies | tcmc new plant investment of roughly NT$700 million · Japanese firms in contract-manufacturing talks |
The four entities point to the same conclusion: designated intractable diseases / orphan diseases are becoming the main battleground of regenerative medicine and cell therapy, and Taiwan's manufacturing capacity (Steminent stem cells, Pell CAR-T) is already deeply embedded in this Taiwan-Japan supply chain.
Risk Factors
Despite the strong momentum, several risks warrant attention:
- Review outcome uncertainty: Although ReproCELL's Stemchymal® is under priority review (a 9-month target), the manufacturing/marketing approval outcome still awaits the determination of the Ministry of Health, Labour and Welfare / PMDA and is not a guaranteed approval.
- Limited earnings impact: ReproCELL explicitly states that this application has a minor impact on current-period earnings, with limited short-term financial contribution.
- Process cost bottleneck: Viral vectors account for roughly 60% of CAR-T process costs, and the cost and yield of autonomous manufacturing remain key variables for Taiwanese firms' expansion.
- Clinical milestone risk: Although Regenephro's RN-014 reached Phase 2a LPLV in 2026, subsequent interim analysis and next-stage trial results remain uncertain.
- Nature of the data: The hard numbers in this card are mostly from corporate PR or press-conference statements (official_statement), not hard figures from financial filings (no TWSE/EDINET official_number); readers should treat them as company self-reported rather than audited financial figures.
FAQ
Q: What is Stemchymal®?
Stemchymal® is a stem cell product (regenerative medicine product) manufactured by Taiwan's Steminent Biotherapeutics, exclusively licensed for commercialization in Japan by ReproCELL, designated in Japan as an orphan regenerative medicine product in December 2018, and targeting the suppression of motor-ataxia progression in spinocerebellar degeneration (types SCA3 and SCA6).
Stemchymal® is a Taiwan-Japan collaboration product, manufactured in Taiwan and brought to market in Japan. The manufacturer is Taiwan's Steminent Biotherapeutics Inc., with sales and shipping in Japan handled by ReproCELL. Its efficacy/effect is the suppression of motor-ataxia progression in spinocerebellar degeneration (types SCA3 and SCA6), and it received orphan regenerative medicine product designation from Japan's Ministry of Health, Labour and Welfare in December 2018 (PRTIMES #1190816).
Q: When was the approval application filed in Japan, and how long will the review take?
The manufacturing/marketing approval application was filed by ReproCELL with the Ministry of Health, Labour and Welfare on 2026-06-24; as an orphan-designation priority-review product, the target is to complete review within 9 months from acceptance of the application.
ReproCELL filed the manufacturing/marketing approval application on 2026-06-24. Because Stemchymal® received orphan regenerative medicine product designation as early as December 2018, this case is a priority-review-eligible product, targeting completion of review within 9 months from acceptance of the application (PRTIMES #1190816).
Q: How many target patients are there for spinocerebellar degeneration?
One criterion for orphan designation is a domestic target patient population of fewer than 50,000 patients; spinocerebellar degeneration is a designated intractable disease in Japan with limited effective treatments, placing it in a high-unmet-need field.
One of the criteria for obtaining orphan regenerative medicine product designation is a domestic target patient population of fewer than 50,000 patients. Spinocerebellar degeneration is a designated intractable disease in Japan, and current effective treatments are limited, so it is a field of high unmet need—which is also the background for the product receiving priority review (PRTIMES #1190816).
Q: How does this relate to Taiwan's cell-therapy industry?
Taiwan-Japan cell therapy shows a bidirectional structure: Taiwan's Steminent stem cell product enters the Japanese market for designated intractable diseases, while Taiwan's Pell CD19 CAR-T manufacturing capacity (tcmc new plant investment of roughly NT$700 million) receives contract-manufacturing inquiries from firms in the United States and Japan.
Stemchymal® itself is manufactured in Taiwan and brought to market in Japan; at the same time, Taiwan's Pell Bio-Med brought online the new plant of its subsidiary tcmc (an investment of roughly NT$700 million), with its main CD19 CAR-T product, and CNA explicitly states that firms in the United States and Japan have entered contract-manufacturing talks. Together these two developments constitute the bidirectional flow of the Taiwan-Japan cell-therapy supply chain: manufacturing capacity in Taiwan, with demand and market entry linked to Japan (CNA #1058478, PRTIMES #1190816).
Q: Why does Japanese regenerative medicine focus on "designated intractable diseases"?
Because designated intractable diseases are mostly high-unmet-need fields with limited effective treatments, they can obtain institutional incentives such as orphan priority review (a 9-month target); recent cases of iPS kidney regeneration (ADPKD) and the myasthenia gravis fund both reflect this trend.
Japan's designated intractable diseases are mostly high-unmet-need fields with limited effective treatments, and institutionally they can obtain incentives such as orphan priority review (e.g., a 9-month review target). Beyond Stemchymal® targeting spinocerebellar degeneration, Regenephro—originating from Kyoto University's CiRA—has reached Phase 2a and raised JPY 1.22 billion for ADPKD (a designated intractable disease); the Kakehashi Fund focused on myasthenia gravis (a designated intractable disease) also launched in May 2026 and raised over JPY 3 million, showing that designated intractable diseases have become the main battleground of regenerative medicine (PRTIMES #1164604, PRTIMES #1175888).
F-Units
F-001: ReproCELL filed a manufacturing/marketing approval application for Stemchymal® with the Ministry of Health, Labour and Welfare on 2026-06-24 - source: PRTIMES #1190816 - source_url: https://prtimes.jp/main/html/rd/p/000000051.000099302.html - source_article_id: 1190816 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026-06-24 - caveat: This is a press release issued by the company itself; acceptance of the application and the review outcome await determination by the Ministry of Health, Labour and Welfare / PMDA
F-002: The efficacy/effect of the Stemchymal® application is suppression of motor-ataxia progression in spinocerebellar degeneration (types SCA3 and SCA6) - source: PRTIMES #1190816 - source_url: https://prtimes.jp/main/html/rd/p/000000051.000099302.html - source_article_id: 1190816 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026-06-24 - caveat: The specific scope of SCA types is subject to the final approval content
F-003: The product received orphan regenerative medicine product designation from the Ministry of Health, Labour and Welfare in December 2018; the manufacturer is Taiwan's Steminent Biotherapeutics Inc., with sales and shipping in Japan handled by ReproCELL - source: PRTIMES #1190816 - source_url: https://prtimes.jp/main/html/rd/p/000000051.000099302.html - source_article_id: 1190816 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2018-12 (designation)
F-004: One criterion for orphan regenerative medicine product designation is a domestic target patient population of fewer than 50,000 patients - source: PRTIMES #1190816 - source_url: https://prtimes.jp/main/html/rd/p/000000051.000099302.html - source_article_id: 1190816 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026-06-24 - caveat: This is a description of the institutional designation criterion, not the actual patient statistic for spinocerebellar degeneration
F-005: As a priority-review-eligible product, this application targets completion of review within 9 months from acceptance - source: PRTIMES #1190816 - source_url: https://prtimes.jp/main/html/rd/p/000000051.000099302.html - source_article_id: 1190816 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026-06-24 - caveat: The "9-month target" is a review-system target timeline, not a guaranteed approval date
F-006: Regenephro completed a first round of fundraising totaling JPY 1.22 billion - source: PRTIMES #1164604 - source_url: https://prtimes.jp/main/html/rd/p/000000011.000129258.html - source_article_id: 1164604 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026 (first-round close)
F-007: Regenephro projects a final total fundraising of JPY 1.7 billion - source: PRTIMES #1164604 - source_url: https://prtimes.jp/main/html/rd/p/000000011.000129258.html - source_article_id: 1164604 - source_type: PRTIMES - confidence: medium - basis: official_statement - period: 2026 (projected) - caveat: JPY 1.7 billion is the projected final fundraising figure (company estimate), not a completed figure
F-008: Regenephro's lead pipeline RN-014 reached last-patient last-visit (LPLV) in its early Phase 2a clinical trial; the target disease is autosomal dominant polycystic kidney disease ADPKD (designated intractable disease), with technology originating from Professor Kenji Osafune of Kyoto University's CiRA - source: PRTIMES #1164604 - source_url: https://prtimes.jp/main/html/rd/p/000000011.000129258.html - source_article_id: 1164604 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026
F-009: The myasthenia gravis "Kakehashi Fund" completed its incorporation and officially launched on 2026-05-27 - source: PRTIMES #1175888 - source_url: https://prtimes.jp/main/html/rd/p/000000003.000185141.html - source_article_id: 1175888 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026-05-27
F-010: The Kakehashi Fund raised donations exceeding its target of JPY 3 million - source: PRTIMES #1175888 - source_url: https://prtimes.jp/main/html/rd/p/000000003.000185141.html - source_article_id: 1175888 - source_type: PRTIMES - confidence: high - basis: official_statement - period: 2026 - caveat: "Over JPY 3 million" is a summary of the post-target actual result, not a precise final amount
F-011: Pell Bio-Med brought online the new plant of its subsidiary tcmc, with an investment of roughly NT$700 million, its main product being CD19 CAR-T - source: CNA #1058478 - source_url: https://www.cna.com.tw/news/afe/202606150221.aspx - source_article_id: 1058478 - source_type: CNA - confidence: high - basis: official_statement - period: 2026-06-15 - caveat: The roughly NT$700 million is a press-conference-stated investment amount, not a figure from financial filings
F-012: Viral vectors account for roughly 60% of CAR-T process costs - source: CNA #1058478 - source_url: https://www.cna.com.tw/news/afe/202606150221.aspx - source_article_id: 1058478 - source_type: CNA - confidence: medium - basis: official_statement - period: 2026-06-15 - caveat: This is a summary proportion of the industry cost structure
F-013: If review proceeds smoothly, Pell's CD19 CAR-T may obtain marketing authorization as early as the end of this year or next year - source: CNA #1058478 - source_url: https://www.cna.com.tw/news/afe/202606150221.aspx - source_article_id: 1058478 - source_type: CNA - confidence: medium - basis: official_statement - period: end of 2026 to 2027 (projected) - caveat: "End of this year or next year" is the company's expected timeline, affected by review progress, not a guaranteed authorization date
J-Units
J-001: Taiwan-Japan cell therapy is forming a bidirectional supply chain of "manufacturing in Taiwan, market entry/demand linked to Japan"—Steminent's stem cell product enters Japan for designated intractable diseases, while Taiwan's Pell CAR-T manufacturing capacity receives contract-manufacturing inquiries from Japanese firms, showing that Taiwan has shifted in the Asia-Pacific cell-therapy division of labor from a purely clinical market to a manufacturing node - confidence: medium - basis_f_units: F-001, F-003, F-011
J-002: Designated intractable diseases / orphan diseases are becoming the main battleground of Japanese regenerative medicine—institutional incentives (orphan priority review with a 9-month target, the fewer-than-50,000-patient criterion) layered on high unmet need attract multiple pathways simultaneously, including stem cells (Stemchymal®), iPS kidney regeneration (RN-014/ADPKD), and patient support funds (myasthenia gravis) - confidence: medium - basis_f_units: F-002, F-004, F-005, F-008, F-009
J-003: Autonomous manufacturing capacity (including key processes such as viral vectors) will be the decisive variable in whether Taiwanese cell-therapy firms can take on Taiwan-Japan contract manufacturing—viral vectors account for roughly 60% of CAR-T process costs, and whoever masters autonomous manufacturing gains bargaining position in the Taiwan-Japan CDMO supply chain - confidence: medium - basis_f_units: F-011, F-012
P-Units
P-001: The final determination outcome and timing of ReproCELL's Stemchymal® manufacturing/marketing approval application—although under priority review (a 9-month target), whether approval is granted and the final scope of efficacy/effect still await determination by the Ministry of Health, Labour and Welfare / PMDA; subsequent announcements should be tracked - status: open
P-002: The actual timing of Pell's CD19 CAR-T marketing authorization, and whether the Japanese firms' contract-manufacturing inquiries convert into formal contracts—both "as early as the end of this year or next year" and "Japanese firms in talks" are early signals; whether they materialize should be observed - status: open
P-003: The interim analysis results and next-stage trial plan for Regenephro's RN-014 after Phase 2a LPLV, and whether the total JPY 1.7 billion fundraising is completed on schedule - status: open
同事件・三視角 / Three Perspectives on the Same Event / 同一イベント・三つの視点
Internal Citation Chain
Published ANK-Docs cited in this article: - ANK-2026-06-24-002 (AI Data Center Construction Boom Drives Taiwan's Heavy-Electrical Industry to Record Highs) → This article draws on its analytical framework of "cross-border Taiwan-Japan supply chains and manufacturing capacity spillover," as the comparative backdrop for understanding how this case's Taiwanese manufacturing capacity (Steminent stem cells, Pell CAR-T) is embedded in the Taiwan-Japan biotech supply chain.
Sources
1. [PRTIMES #1190816] ReproCELL Incorporated, "Notice Regarding the Manufacturing and Marketing Approval Application for the Regenerative Medicine Product 'Stemchymal®' Targeting Spinocerebellar Degeneration", 2026-06-24. https://prtimes.jp/main/html/rd/p/000000051.000099302.html 2. [PRTIMES #1164604] Regenephro Inc., "iPS Cell-Derived Kidney Regenerative Medicine: Total JPY 1.22 Billion Fundraising / RN-014 Phase 2a LPLV", 2026. https://prtimes.jp/main/html/rd/p/000000011.000129258.html 3. [PRTIMES #1175888] Myasthenia Gravis Kakehashi Fund, "Notice of Completion of Incorporation and Commencement of Activities of the Myasthenia Gravis Kakehashi Fund", 2026-05-27. https://prtimes.jp/main/html/rd/p/000000003.000185141.html 4. [CNA #1058478] Central News Agency, "Pell Bio-Med Aims for CD19 CAR-T Authorization by Year-End; tcmc Plant Launched for Cell Therapy / US and Japanese Firms in Contract-Manufacturing Talks", 2026-06-15. https://www.cna.com.tw/news/afe/202606150221.aspx 5. [ANK-2026-06-24-002] Rin Takenouchi, "AI Data Center Construction Boom Drives Taiwan's Heavy-Electrical Industry to Record Highs: Four Plants' Revenues Climb in Unison, Hua Eng AIDC Orders Exceed NT$20 Billion, Shihlin Electric's Visibility Extends to 2030", 2026-06-24. https://ainews.washinmura.jp/ainews/zh/ank/ANK-2026-06-24-002